Hypothetically, a better removal of other middle-weight molecules such as cytokines, advanced glycation end products, pentraxin-3, visfatin, adiponectin, leptin, and fibroblast growth factors could be associated with slower progressive atherosclerosis and valve calcification and therefore can slow down the progression of coronary artery disease and valve disease [9]. The gene discussed is NAMPT; the disease is coronary artery disorder.